Replies to post #61304 on Biotech Values

[nuere]

In just a couple of months OXGN will have a partner for its VDA zybrestat, possibly also the next generation VDA, oxi4503. Could be a deal in oncology + ophthalmology or in just one indication. I doubt the deal will be as good as the one antisoma got with novartis but who knows.

[jbog]

Dew,,,,

On antisoma's web site the have a couple trial results listed (right side) . They look very interesting.


http://www.antisoma.com/asm/products/asa404/